Butyrate Frequently Asked Questions

---

The mucus layer in the colon acts as a protective shield that separates gut microbes from the intestinal lining, reducing the risk of tissue damage and inflammation. It also serves as a lubricant, helping stool pass smoothly through the colon. Beyond this, mucus plays an important role in immune defense by carrying antimicrobial molecules and antibodies that neutralize harmful pathogens. At the same time, it supports a healthy microbiome by providing nutrients to beneficial bacteria. Altogether, this barrier is essential for maintaining gut integrity, preventing infection, and ensuring a balanced relationship between the host and its microbes. Unfortunately, mucul layer decreases with age [1]. Butyrate increases mucus secretion from goblet cells, thickening the mucosal layer that acts as another defense line against bacterial intrusion [2]. Butyrate is a primary energy source for colonocytes (cells lining the colon), supporting their health and function. Healthy colonocytes are essential for a robust intestinal barrier.

Recent studies show that sodium butyrate can enhance mucin production and support the integrity of the gut barrier. Such function is extremely important as leaky gut leads to numerous inflammatory diseases that ultimately affect the whole body. Sodium butyrate supports gut barrier integrity by promoting the expression of genes related to tight junction proteins and mucins. Animal studies and cell-based experiments show that supplementation with sodium butyrate improves the intestinal barrier, reduces permeability, and thus decreases symptoms associated with leaky gut [3].

As mentioned earlier, specialized colon cells, called goblet cells, are responsible for mucin production. In older humans, there is a measurable decrease in goblet cell numbers and the amount of mucin content per unit area in the colon. Additionally, degenerative changes are observed in mucin production, leading to a compromised mucus barrier in the elderly colon [4]. 

References:

1. Sovran, Bruno et al. “Age-associated Impairment of the Mucus Barrier Function is Associated with Profound Changes in Microbiota and Immunity.” Scientific reports vol. 9,1 1437. 5 Feb. 2019, doi:10.1038/s41598-018-35228-3

2. Singh, Vineet et al. “Butyrate producers, "The Sentinel of Gut": Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics.” Frontiers in microbiology vol. 13 1103836. 12 Jan. 2023, doi:10.3389/fmicb.2022.1103836

3. He, Hanchang et al. “Sodium Butyrate Ameliorates Gut Microbiota Dysbiosis in Lupus-Like Mice.” Frontiers in nutrition vol. 7 604283. 11 Nov. 2020, doi:10.3389/fnut.2020.604283

4. Baidoo, Nicholas, and Gareth J Sanger. “Age-related decline in goblet cell numbers and mucin content of the human colon: Implications for lower bowel functions in the elderly.” Experimental and molecular pathology vol. 139 (2024): 104923. doi:10.1016/j.yexmp.2024.104923

Inflammation is a fundamental immune response designed to protect the body from injury and infection. When tightly regulated, it promotes healing and restores tissue integrity. However, when inflammation becomes chronic or dysregulated—as commonly occurs with aging, stress, infection, or microbiome imbalance—it contributes to the development of numerous diseases, including inflammatory bowel disease (IBD), metabolic disorders, cardiovascular disease, autoimmune conditions, and neurodegenerative disorders. The gut plays a central role in regulating systemic inflammation, as it is both a major immune organ and the primary interface between the host and trillions of microbes.

Butyrate, a short-chain fatty acid (SCFA) produced by beneficial gut bacteria through the fermentation of dietary fiber, is one of the most powerful endogenous anti-inflammatory molecules in the human body. Its anti-inflammatory effects are exerted through multiple, complementary mechanisms that operate locally in the gut and systemically throughout the body.

At the intestinal level, butyrate directly suppresses excessive immune activation. It inhibits the activation of nuclear factor kappa B (NF-κB), a master transcription factor that controls the expression of many pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6 [1]. By dampening NF-κB signaling in intestinal epithelial cells and immune cells, butyrate reduces the production of inflammatory mediators that drive tissue damage and chronic inflammation. This effect is particularly important in the colon, where constant exposure to microbial antigens requires precise immune tolerance. 

Butyrate also plays a critical role in shaping immune cell behavior. It promotes the differentiation and expansion of regulatory T cells (Tregs) [2], a specialized immune population responsible for suppressing excessive inflammatory responses and maintaining immune tolerance. Increased Treg activity helps prevent inappropriate immune attacks on host tissues and commensal microbes. At the same time, butyrate suppresses the activation of pro-inflammatory macrophages and dendritic cells, shifting the immune environment from a reactive, inflammatory state toward a balanced and regulatory one.

Beyond immune signaling, butyrate exerts epigenetic control over inflammation. It functions as a natural histone deacetylase (HDAC) inhibitor [3], altering gene expression patterns in immune and epithelial cells. Through HDAC inhibition, butyrate downregulates genes associated with inflammation while upregulating genes involved in barrier maintenance, stress resistance, and cellular repair. This epigenetic modulation provides a durable, systems-level mechanism by which butyrate supports long-term immune homeostasis rather than short-lived symptom suppression.

Importantly, butyrate’s anti-inflammatory effects are closely tied to its role in maintaining gut barrier integrity. A compromised intestinal barrier allows bacterial components such as lipopolysaccharide (LPS) to enter the bloodstream, triggering systemic inflammation—a phenomenon often referred to as metabolic endotoxemia. By strengthening tight junctions, supporting mucus production, and fueling colonocytes, butyrate reduces gut permeability and limits the translocation of inflammatory microbial products into circulation. This gut-centered mechanism helps explain why low butyrate levels are consistently associated with chronic inflammatory diseases both inside and outside the gastrointestinal tract.

Systemically, butyrate-derived signaling influences inflammation in peripheral tissues, including the liver, adipose tissue, vasculature, and brain. Reduced circulating inflammatory cytokines and improved immune tolerance have been observed in both animal models and human studies following butyrate supplementation or increased endogenous production. These effects are increasingly recognized as relevant not only for gut disorders, but also for conditions such as insulin resistance, cardiovascular disease, and neuroinflammation.

Unfortunately, modern lifestyles—characterized by low fiber intake, antibiotic exposure, chronic stress, and aging—are associated with reduced populations of butyrate-producing bacteria and lower intestinal butyrate levels. This decline weakens the body’s natural anti-inflammatory defenses, contributing to a persistent, low-grade inflammatory state that underlies many chronic diseases. Restoring butyrate levels, either by supporting endogenous production or through targeted supplementation, represents a powerful strategy to reestablish immune balance and protect long-term health.

References:

1. Segain JP, Raingeard de la Blétière D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut. 2000;47(3):397-403. doi:10.1136/gut.47.3.397

2. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446-450. doi:10.1038/nature12721

3. Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2014;111(6):2247-2252. doi:10.1073/pnas.1322269111 

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation, pain, swelling, and progressive destruction of cartilage and bone. While RA primarily affects the joints, it is increasingly recognized as a systemic condition driven by widespread immune dysregulation. In individuals with RA, immune tolerance fails, leading to sustained activation of inflammatory pathways that damage both local joint tissue and distant organs.

Growing evidence suggests that the gut plays an important upstream role in rheumatoid arthritis. The gastrointestinal tract is a major immune organ, constantly educating immune cells to distinguish between harmless signals and true threats. In RA, this immune education process appears to be disrupted. Patients with RA frequently exhibit alterations in gut microbiota composition, reduced microbial diversity, and impaired production of beneficial microbial metabolites, particularly short-chain fatty acids such as butyrate.

Butyrate plays a central role in maintaining immune balance. One of its most important functions in the context of RA is the regulation of immune cell behavior. RA is associated with an imbalance between pro-inflammatory T helper cells (including Th1 and Th17 cells) and regulatory T cells (Tregs), which normally suppress excessive immune responses. Butyrate promotes the differentiation and expansion of Tregs, helping restore immune tolerance and reduce autoimmune-driven inflammation [1, 2].

At the molecular level, butyrate suppresses inflammatory signaling pathways that are central to RA pathogenesis. It inhibits activation of nuclear factor kappa B (NF-κB), a key transcription factor that drives the expression of pro-inflammatory cytokines such as tumor necrosis factor–α (TNF-α), interleukin-6 (IL-6), and interleukin-17 (IL-17). These cytokines are major contributors to synovial inflammation, cartilage degradation, and bone erosion in rheumatoid arthritis. By reducing their expression, butyrate helps dampen the inflammatory cascade that fuels joint damage [3]. Anti-inflammatory butyrate-producing bacteria, such as Faecalibacterium prausnitzii, were shown to provide a beneficial effect in the RA mouse model by attenuating IL-17 levels [4]. 

Butyrate also exerts epigenetic control over immune responses. As a natural histone deacetylase (HDAC) inhibitor, butyrate alters gene expression patterns in immune cells, shifting them away from a pro-inflammatory phenotype and toward a more regulated, tolerant state. This epigenetic regulation allows butyrate to promote longer-lasting immune stability rather than short-term suppression of symptoms, a feature that is especially relevant in chronic autoimmune diseases such as RA [5].

In addition to its direct effects on immune cells, butyrate indirectly influences RA by supporting gut barrier integrity. Increased intestinal permeability, often referred to as “leaky gut,” has been observed in RA and allows bacterial components to enter the bloodstream, triggering systemic inflammation and worsening autoimmune activity. By strengthening tight junctions, supporting mucus production, and fueling intestinal epithelial cells, butyrate helps reduce the translocation of inflammatory microbial products and lowers systemic immune activation.

Animal studies provide further support for butyrate’s role in RA. In experimental models of inflammatory arthritis, oral supplementation with sodium butyrate reduces joint swelling, inflammatory cell infiltration, and cartilage destruction while increasing regulatory immune responses. These findings suggest that restoring butyrate signaling can mitigate both local joint inflammation and systemic immune dysregulation [6].

Unfortunately, factors common in modern life—including low dietary fiber intake, antibiotic exposure, chronic stress, and aging—are associated with reduced populations of butyrate-producing bacteria and lower intestinal butyrate levels. This decline may weaken natural immune-regulatory mechanisms and increase susceptibility to autoimmune diseases such as rheumatoid arthritis. Supporting butyrate levels, either by enhancing endogenous production or through targeted supplementation, represents a strategy aimed at addressing upstream immune imbalance rather than solely managing downstream inflammation.

References

1. Furusawa,      Y., Obata, Y., Fukuda, S. et al. Commensal      microbe-derived butyrate induces the differentiation of colonic regulatory      T cells. Nature 504, 446–450      (2013). https://doi.org/10.1038/nature12721

2. Pang      A, Pu S, Pan Y, Huang N, Li D. Short-chain fatty acids from gut microbiota      restore Th17/Treg balance in rheumatoid arthritis: Mechanisms and      therapeutic potential. J Transl Autoimmun. 2025;11:100316. Published 2025 Sep 16.      doi:10.1016/j.jtauto.2025.100316

3. Chang      PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate      regulates intestinal macrophage function via histone deacetylase      inhibition. Proc Natl Acad Sci U S A. 2014;111(6):2247-2252. doi:10.1073/pnas.1322269111

4. Moon,      J., Lee, A. R., Kim, H., Jhun, J., Lee, S. Y., Choi, J. W., Jeong, Y.,      Park, M. S., Ji, G. E., Cho, M. L., & Park, S. H. (2023).      Faecalibacterium prausnitzii alleviates inflammatory arthritis and      regulates IL-17 production, short chain fatty acids, and the intestinal      microbial flora in experimental mouse model for rheumatoid arthritis. Arthritis research & therapy, 25(1), 130.      https://doi.org/10.1186/s13075-023-03118-3

5. Koh      A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to      Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell.      2016;165(6):1332-1345. doi:10.1016/j.cell.2016.05.041

6. Hui W, Yu D, Cao Z, Zhao X. Butyrate inhibit collagen-induced arthritis via Treg/IL-10/Th17 axis. Int Immunopharmacol. 2019;68:226-233. doi:10.1016/j.intimp.2019.01.018

Coming soon

Coming soon

Coming soon

Coming soon

Coming soon

The above statements are based on extensive research but have not been evaluated by the Food and Drug Administration (FDA). Therefore, this product is not intended to diagnose, treat, cure or prevent any disease.